



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Walke and Scoville

Application No.: 10/008,574

Filed: October 26, 2001

Title: Novel Human 7TM Proteins and Polynucleotides
Encoding the Same

Attorney Docket No.: LEX-0264-USA

Group Art Unit: 1645 #17

Examiner: To Be Assigned

Assistant Commissioner for Patents
Box DD
Arlington, VA 22202

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

This Supplemental Information Disclosure Statement is submitted:

X under 37 CFR 1.97(b), or

(Within three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

— under 37 CFR 1.97(c) together with either a:

— Certification under 37 CFR 1.97(e), or

— a \$240.00 fee under 37 CFR 1.17(p), or

(After the CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

— under 37 CFR 1.97(d) together with a:

— Certification under 37 CFR 1.97(e), and

— a petition under 37 CFR 1.97(d)(2)(ii), and

— a \$130.00 petition fee set forth in 37 CFR 1.17(i)(1).

(Filed after final action or notice of allowance, whichever occurs first, but before payment of the issue fee)

I, the applicant, patents, publications or other information of which applicant(s) are aware, which applicant(s) believes(s) may be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56.

The relevance of the attached references is that under 37 CFR § 1.97 (e)(1) each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application corresponding to the above-identified application not more than three (3) months prior to the filing of this Information Disclosure Statement.

Applicant submits that the above references taken alone or in combination neither anticipate nor render obvious the present invention. Consideration of the foregoing in relation to this application is respectfully requested.

The Commissioner is hereby authorized to charge any additional fee required or credit any overpayment for this Information Disclosure Statement to Lexicon Genetics Deposit Account No. 50-0892. A copy of this sheet is enclosed.

It is requested that the information disclosed herein be made of record in this application.

Respectfully submitted,

March 19, 2003
Date

Lance K. Ishimoto Reg. No. 41,866
Lance K. Ishimoto Reg. No. 41,866

LEXICON GENETICS INCORPORATED
8800 Technology Forest Place
The Woodlands, TX 77381
(281) 863-3333



24231

PATENT TRADEMARK OFFICE

Under the Paperwork Reduction Project of 1995, no persons are required to
 1
 2
 3
 4
 5
 6
 7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
 100
 101
 102
 103
 104
 105
 106
 107
 108
 109
 110
 111
 112
 113
 114
 115
 116
 117
 118
 119
 120
 121
 122
 123
 124
 125
 126
 127
 128
 129
 130
 131
 132
 133
 134
 135
 136
 137
 138
 139
 140
 141
 142
 143
 144
 145
 146
 147
 148
 149
 150
 151
 152
 153
 154
 155
 156
 157
 158
 159
 160
 161
 162
 163
 164
 165
 166
 167
 168
 169
 170
 171
 172
 173
 174
 175
 176
 177
 178
 179
 180
 181
 182
 183
 184
 185
 186
 187
 188
 189
 190
 191
 192
 193
 194
 195
 196
 197
 198
 199
 200
 201
 202
 203
 204
 205
 206
 207
 208
 209
 210
 211
 212
 213
 214
 215
 216
 217
 218
 219
 220
 221
 222
 223
 224
 225
 226
 227
 228
 229
 230
 231
 232
 233
 234
 235
 236
 237
 238
 239
 240
 241
 242
 243
 244
 245
 246
 247
 248
 249
 250
 251
 252
 253
 254
 255
 256
 257
 258
 259
 260
 261
 262
 263
 264
 265
 266
 267
 268
 269
 270
 271
 272
 273
 274
 275
 276
 277
 278
 279
 280
 281
 282
 283
 284
 285
 286
 287
 288
 289
 290
 291
 292
 293
 294
 295
 296
 297
 298
 299
 300
 301
 302
 303
 304
 305
 306
 307
 308
 309
 310
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 322
 323
 324
 325
 326
 327
 328
 329
 330
 331
 332
 333
 334
 335
 336
 337
 338
 339
 340
 341
 342
 343
 344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362
 363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376
 377
 378
 379
 380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417
 418
 419
 420
 421
 422
 423
 424
 425
 426
 427
 428
 429
 430
 431
 432
 433
 434
 435
 436
 437
 438
 439
 440
 441
 442
 443
 444
 445
 446
 447
 448
 449
 450
 451
 452
 453
 454
 455
 456
 457
 458
 459
 460
 461
 462
 463
 464
 465
 466
 467
 468
 469
 470
 471
 472
 473
 474
 475
 476
 477
 478
 479
 480
 481
 482
 483
 484
 485
 486
 487
 488
 489
 490
 491
 492
 493
 494
 495
 496
 497
 498
 499
 500
 501
 502
 503
 504
 505
 506
 507
 508
 509
 510
 511
 512
 513
 514
 515
 516
 517
 518
 519
 520
 521
 522
 523

Complete if Known

Application Number	10/008,574
Filing Date	Oct 26, 2001
First Named Inventor	Walke
Group Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	LEX-0264-USA

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U S Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office	Number ⁴	Kind Code ⁵ (if known)				
	DX		WO 02 22665 A		Takeda Chemical Industries	03-21-2002		
	DY		WO 02 26825 A		Incyte Genomics	04-04-2002		
	DZ		WO 02 29050 A		Bayer Aktiengesellschaft	04-11-2002		
	FA		WO 02 29051 A		Bayer Aktiengesellschaft	04-11-2002		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	EB	DATABASE EMBL 19 May 2000, CORBY N.: "Human DNA sequence from clone RP11-550C4 on chromosome 6", Database accession no. AL356421, XP002229817, Postions 56940-58380	
	EC	DATABASE EMBL 22 March 2000, SIMS S.: "Human DNA sequence from clone RP11-337K13 "Sequencing cancelled"", Database accession no. AL161776, XP002229818, Positions 119530-120990	
	ED	ICHTCHENKO K ET AL: "A NOVEL UBIQUITOUSLY EXPRESSED ALPHA-LATROTOXIN RECEPTOR IS A MEMBER OF THE CIRL FAMILY OF G-PROTEIN-COUPLED RECEPTORS" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 9, 26 February 1999, pages 5491-5498, XP000828192, ISSN: 0021-9258	
	EE	LELIANOVA V G ET AL: "ALPHA-LATROTOXIN RECEPTOR, LATROPHILIN, IS A NOVEL MEMBER OF THE SECRETIN FAMILY OF G PROTEIN-COUPLED RECEPTORS: JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 272, no. 34, 22 August 1997, pages 21504-21508, XP002066460, issn: 0021-9258	
	EF	OSTERHOFF C ET AL: "CLONING OF A HUMAN EPIDIDYMIS-SPECIFIC MRNA, HE6, ENCODING A NOVEL MEMBER OF THE SEVEN TRANSMEMBRANE-DOMAIN RECEPTRO SUPERFAMILY" DNA AND CELL BIOLOGY, NEW YORK, NY, US, vol. 16, no. 4, 1997, pages 379-389, XP002925525, ISSN:1044-5498	
	EG	STADEL J M ET AL: "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER TRENDS JOURNAL, CAMBRIDGE, GB, vol. 18, no. 11, 1 November 1997, pages 430-437, XP004099345, ISSN 0165-6147.	
	EH	SUGITA S ET AL: "ALPHA-LATROTOXIN RECEPTOR CIRL/LATROPHILIN 1 (CL1) DEFINES AN UNUSUAL FAMILY OF UBIQUITOUS G-PROTEIN-LINKED RECEPTORS" JOURNAL OF BIOLOGICAL CHEMISTRY, THE AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, INC., US, vol. 273, no. 49, 1998, pages 32715-32724, XP000946649, issn: 0021-9258	
	ET	International Search Report	

[illegible]

Budgetary Statement: This form is estimated. Take 50% of the amount shown and add it to the amount shown in the budgetary statement. The total amount shown in the budgetary statement is the amount that will be paid to the contractor.

Please type a plus sign (+) inside this box → ☐

PTO/SB.21 (08-00)

Approval for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/008,574

Filing Date

Oct 26, 2001

First Named Inventor

Walke, D. Wade

Group Art Unit

1645

Examiner Name

Not Yet Assigned

Total Number of Pages in This Submission

5 pgs +
12 references

Attorney Docket Number

LEX-0264-USA

ENCLOSURES (check all that apply)

☐ Fee Transmittal Form

☐ Fee Attached

☐ Amendment / Reply

☐ After Final

☐ Affidavits/declaration(s)

☐ Extension of Time Request

☐ Express Abandonment Request

☒ Supplemental Information Disclosure Statement

☐ Certified Copy of Priority Document(s)

☐ Response to Missing Parts/Incomplete Application

☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

☐ Assignment Papers (for an Application)

☐ Drawing(s)

☐ Licensing-related Papers

☐ Petition

☐ Petition to Convert to a Provisional Application

☐ Power of Attorney, Revocation Change of Correspondence Address

☐ Terminal Disclaimer

☐ Request for Refund

☐ CD, Number of CD(s) _____

Remarks

☐ After Allowance Communication to Group

☐ Appeal Communication to Board of Appeals and Interferences

☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)

☐ Proprietary Information

☐ Status Letter

☒ Other Enclosure(s) (please identify below):

- Return Postcard
- Supplemental Form PTO1449 and Copies of (12) References Cited
- International Search Report as Ref EI

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm

Lexicon Genetics Incorporated

or

Individual name

Lance K. Ishimoto

Reg. No. 41,866

Signature

Lance K. Ishimoto by David W. H. Allen



24231

PATENT TRADEMARK OFFICE

Date

March 19, 2003

CERTIFICATE OF MAILING

Typed or printed name

Michelle Klein

Signature

Michelle Klein

Date

March 19, 2003